Smoldering multiple myeloma (SMM) is an asymptomatic precursor condition of multiple myeloma (MM). With the introduction of novel therapies that offer high efficiency and improved tolerability, diagnostic criteria have been established to identify patients who may benefit from early therapy. The International Myeloma Working Group (IMWG) and ESMO include a free light chain (FLC) ratio of ≥100 among several accepted criteria and clinical practice guidelines.
Early therapy in smoldering multiple myeloma: use of FLC ratio with N Latex FLC assaysClinical study examines assay performance to help assess risk of disease progression in patients with smoldering multiple myeloma
FLC ratio white paper
FLC ratio white paper available for download
Siemens Healthineers has prepared a concise, information-packed white paper summarizing important issues surrounding the diagnosis of SMM, FLC ratio, and early MM therapy. Topics covered include:
- Evolution of diagnostic criteria for MM
- Inability to use different FLC assay and/or analyzer results interchangeably
- Inability to determine risk and cutoffs using correlation analysis
- A summary of six published studies that describe the identification of ultra- and very-high-risk SMM patients using both N Latex FLC and/or FREELITE assays
Access to N Latex FLC validation study results
A recently published French study confirmed that accepted IMWG recommendations to evaluate the risk of progression established using the FREELITE assays can be applied to N Latex FLC assays with equivalent results. The research was conducted among a large cohort of SMM patients with required clinical follow-up for at least 2 years. Access the published article to review the complete study design, detailed correlation graphs, and author discussion.